Detalles de la búsqueda
1.
Decitabine in Older Patients with AML: Quality of Life Results of the EORTC-GIMEMA-GMDS-SG Randomized Phase III Trial.
Blood
; 2024 May 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-38717861
2.
Gemtuzumab ozogamicin plus midostaurin in combination with standard '7 + 3' induction therapy in newly diagnosed AML: Results from the SAL-MODULE phase I study.
Br J Haematol
; 2024 Apr 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-38593353
3.
CEBPA mutations in 4708 patients with acute myeloid leukemia: differential impact of bZIP and TAD mutations on outcome.
Blood
; 139(1): 87-103, 2022 01 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-34320176
4.
Multicenter development of a PET-based risk assessment tool for product-specific outcome prediction in large B-cell lymphoma patients undergoing CAR T-cell therapy.
Eur J Nucl Med Mol Imaging
; 51(5): 1361-1370, 2024 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-38114616
5.
Does time from diagnosis to treatment affect the prognosis of patients with newly diagnosed acute myeloid leukemia?
Blood
; 136(7): 823-830, 2020 08 13.
Artículo
en Inglés
| MEDLINE | ID: mdl-32496541
6.
Characteristics and outcome of patients with low-/intermediate-risk acute promyelocytic leukemia treated with arsenic trioxide: an international collaborative study.
Haematologica
; 106(12): 3100-3106, 2021 12 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-34047178
7.
Etoposide Combined with FLAG Salvage Therapy Is Effective in Multiple Relapsed/Refractory Acute Myeloid leukemia.
Acta Haematol
; 143(5): 438-445, 2020.
Artículo
en Inglés
| MEDLINE | ID: mdl-31655809
8.
Measurable residual disease-guided treatment with azacitidine to prevent haematological relapse in patients with myelodysplastic syndrome and acute myeloid leukaemia (RELAZA2): an open-label, multicentre, phase 2 trial.
Lancet Oncol
; 19(12): 1668-1679, 2018 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-30442503
9.
International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts.
Blood
; 126(3): 291-9, 2015 Jul 16.
Artículo
en Inglés
| MEDLINE | ID: mdl-25987659
10.
Cyclophosphamide-based stem cell mobilization in relapsed multiple myeloma patients: A subgroup analysis from the phase III trial ReLApsE.
Eur J Haematol
; 99(1): 42-50, 2017 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-28370401
11.
Rationale and design of the German-Speaking Myeloma Multicenter Group (GMMG) trial ReLApsE: a randomized, open, multicenter phase III trial of lenalidomide/dexamethasone versus lenalidomide/dexamethasone plus subsequent autologous stem cell transplantation and lenalidomide maintenance in patients with relapsed multiple myeloma.
BMC Cancer
; 16: 290, 2016 Apr 25.
Artículo
en Inglés
| MEDLINE | ID: mdl-27114074
12.
Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trial.
Lancet Oncol
; 16(16): 1691-9, 2015 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-26549589
13.
EZH2 mutations and impact on clinical outcome: an analysis in 1,604 patients with newly diagnosed acute myeloid leukemia.
Haematologica
; 105(5): e228-e231, 2020 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-31413097
14.
Safety and efficacy of vismodegib in relapsed/refractory acute myeloid leukaemia: results of a phase Ib trial.
Br J Haematol
; 185(3): 595-598, 2019 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-30203489
15.
Outcome Prediction in Patients With Large B-cell Lymphoma Undergoing Chimeric Antigen Receptor T-cell Therapy.
Hemasphere
; 7(1): e817, 2023 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-36698613
16.
UBTF tandem duplications are rare but recurrent alterations in adult AML and associated with younger age, myelodysplasia, and inferior outcome.
Blood Cancer J
; 13(1): 88, 2023 05 26.
Artículo
en Inglés
| MEDLINE | ID: mdl-37236968
17.
10-day decitabine versus 3â+â7 chemotherapy followed by allografting in older patients with acute myeloid leukaemia: an open-label, randomised, controlled, phase 3 trial.
Lancet Haematol
; 10(11): e879-e889, 2023 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-37914482
18.
Differential impact of IDH1/2 mutational subclasses on outcome in adult AML: results from a large multicenter study.
Blood Adv
; 6(5): 1394-1405, 2022 03 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-34794176
19.
A proof of concept phase I/II pilot trial of LSD1 inhibition by tranylcypromine combined with ATRA in refractory/relapsed AML patients not eligible for intensive therapy.
Leukemia
; 35(3): 701-711, 2021 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-32561840
20.
Loss-of-Function Mutations of BCOR Are an Independent Marker of Adverse Outcomes in Intensively Treated Patients with Acute Myeloid Leukemia.
Cancers (Basel)
; 13(9)2021 Apr 26.
Artículo
en Inglés
| MEDLINE | ID: mdl-33926021